Seminars in Oncology Nursing
Volume 23, Issue 3 , Pages 184-190 , August 2007

Extravasation Management

  • Lisa Schulmeister

      Affiliations

    • Corresponding Author InformationAddress correspondence to Lisa Schulmeister, RN, MN, CS, APRN-BC, OCN®, FAAN, 282 Orchard Road, River Ridge, LA 70123-2648

References 

  1. Bozkurt AK, Uzel B, Akman C, et al. Intrathoracic extravasation of antineoplastic agents: case report and systematic review. Am J Clin Oncol. 2003;26:121–123
  2. Ener RA, Meglathery SB, Styler M. Extravasation of systemic hemato-oncological therapies. Ann Oncol. 2004;15:858–862
  3. Cox RF. Managing skin damage induced by doxorubicin hydrochloride and daunorubicin hydrochloride. Am J Hosp Pharm. 1984;41:2410–2414
  4. Luedke DW, Kennedy PS, Rietschel RL. Histopathogenesis of skin and subcutaneous injury induced by adriamycin. Plas Reconstr Surg. 1979;63:463–465
  5. Langstein HN, Duman H, Seelig D, et al. Retrospective study of the management of chemotherapeutic extravasation injury. Ann Plast Surg. 2002;49:369–374
  6. Barlock AL, Howser DM, Hubbard SM. Nursing management of adriamycin extravasation. Am J Nurs. 1979;79:94–96
  7. Schrijvers DL. Extravasation: a dreaded complication of chemotherapy. Ann Oncol. 2003;14(suppl 3):26–30
  8. Kassner E. Evaluation and treatment of chemotherapy extravasation injuries. J Pediatr Oncol Nurs. 2000;17:135–148
  9. Polovich M, White JM, Kelleher LO. Chemotherapy and biotherapy guidelines and recommendations for practice. In: Ed 2. Pittsburgh, PA: Oncology Nursing Society; 2005;p. 82–83
  10. Goolsby TV, Lombardo FA. Extravasation of chemotherapeutic agents: prevention and treatment. Semin Oncol. 2006;33:139–143
  11. Heitmann C, Durmas C, Ingianni G. Surgical management after doxorubicin and epirubicin extravasation. J Hand Surg. 1998;23:666–668
  12. Larson DL. What is the appropriate management of tissue extravasation by antitumor agents?. Plast Reconstr Surg. 1985;75:397–405
  13. Schulmeister L, Camp-Sorrell D. Extravasations from implanted ports. Oncol Nurs Forum. 2000;27:531–540
  14. Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer. 1982;49:1796–1799
  15. Cedidi C, Hierner R, Berger A. Plastic surgical management in tissue extravasation of cytotoxic agents in the upper extremity. Eur J Med Res. 2001;6:309–314
  16. Cohen FJ, Manganaro J, Bezozo RC. Identification of involved tissue during surgical treatment of doxorubicin-induced extravasation necrosis. J Hand Surg [Am]. 1983;8:43–45
  17. Andersson AP, Dahlstrom KK. Clinical results after doxorubicin extravasation treated with excision guided by fluorescence microscopy. Eur J Cancer. 1993;29:1712–1714
  18. Dahlstrom KK, Chenoufi HL, Daugaard S. Fluorescence microscopic demonstration and demarcation of doxorubicin extravasation (Experimental and clinical studies). Cancer. 1990;65:1722–1726
  19. Scuderi N, Onesti MG. Antitumor agents: extravasation, management, and surgical treatment. Ann Plast Surg. 1994;32:39–44
  20. Vandeweyer E, Deraemaecker R. Early surgical suction and washout for treatment of cytotoxic drug extravasations. Acta Chir Belg. 1994;100:37–38
  21. Fleming A, Butler B, Gault D. Letter to the editor in response to “Surgical management after doxorubicin and epirubicin extravasation.”. J Hand Surg [Br]. 1998;24:390
  22. Gault DT. Extravasation injuries. Br J Plast Surg. 1993;46:91–96
  23. Giunta R. Early subcutaneous wash-out in acute extravasations. Ann Oncol. 2004;15:1146
  24. Van Wijck R. Liposuction to the radiologist’s rescue. Plast Reconstr Surg. 1993;92:175
  25. Yilmaz M, Demirdover D, Mola F. Treatment options in extravasation injury: an experimental study in rats. Plast Reconstr Surg. 2001;109:2418–2423
  26. Dorr RT, Soble M, Alberts DS. Efficacy of sodium thiosulfate as a local antidote to mechlorethamine skin toxicity. Cancer Chemother Pharmacol. 1988;22:299–302
  27. Bertelli G, Dini D, Forno BG, et al. Hyaluronidase as an antidote to extravasation of vinca alkaloids: clinical results. J Cancer Res Clin Oncol. 1994;120:505–506
  28. Laurie SW, Wilson KL, Kernahan DA, et al. Intravenous extravasation injuries: the effectiveness of hyaluronidase in their treatment. Ann Plast Surg. 1984;13:191–194
  29. Langer SW, Sehested M, Jensen PB. Treatment of anthracycline extravasation with dexrazoxane. Clin Cancer Res. 2000;6:3680–3686
  30. Langer SW, Sehested M, Jensen PB. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Ann Oncol. 2000;12:405–410
  31. Giaccone G. Successful treatment of anthracycline extravasation with Savene (dexrazoxane). Results from two multicenter prospective clinical studies. Presentation at the 31st Congress of the European Society for Medical Oncology, Istanbul, Turkey. Available at: http://www.savene.com/multimedia/Giaccone_presentation_V2a.pdf (accessed December 7, 2006).
  32. Mouridsen HT, Langer SW, Buter J, et al. Treatment of anthracycline extravasation with Savene (dexrazoxane) (Results from two prospective clinical multicentre studies). Ann Oncol. 2007;18:546–550
  33. Schulmeister L. Managing extravasations. Clin J Oncol Nurs. 2005;9:472–475

PII: S0749-2081(07)00053-8

doi: 10.1016/j.soncn.2007.05.003

Seminars in Oncology Nursing
Volume 23, Issue 3 , Pages 184-190 , August 2007

Article Tools

* Image Usage & Resolution